DE69534100D1 - Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen - Google Patents

Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen

Info

Publication number
DE69534100D1
DE69534100D1 DE69534100T DE69534100T DE69534100D1 DE 69534100 D1 DE69534100 D1 DE 69534100D1 DE 69534100 T DE69534100 T DE 69534100T DE 69534100 T DE69534100 T DE 69534100T DE 69534100 D1 DE69534100 D1 DE 69534100D1
Authority
DE
Germany
Prior art keywords
macrophages
cancerous
diagnosis
clonal
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69534100T
Other languages
English (en)
Other versions
DE69534100T2 (de
Inventor
Michael S Mcgrath
Brian Herndier
Bruce Shiramizu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/286,745 external-priority patent/US5580715A/en
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69534100D1 publication Critical patent/DE69534100D1/de
Publication of DE69534100T2 publication Critical patent/DE69534100T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
DE69534100T 1994-08-05 1995-08-01 Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen Expired - Fee Related DE69534100T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/286,745 US5580715A (en) 1994-08-05 1994-08-05 Diagnosis of cancer having clonal macrophage involvement
US08/473,040 US5639600A (en) 1994-08-05 1995-06-06 Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US473040 1995-06-06
PCT/US1995/009715 WO1996004019A1 (en) 1994-08-05 1995-08-01 Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US286745 1999-04-06

Publications (2)

Publication Number Publication Date
DE69534100D1 true DE69534100D1 (de) 2005-04-28
DE69534100T2 DE69534100T2 (de) 2006-03-23

Family

ID=26964048

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534100T Expired - Fee Related DE69534100T2 (de) 1994-08-05 1995-08-01 Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen

Country Status (8)

Country Link
US (1) US5639600A (de)
EP (1) EP0772456B1 (de)
JP (1) JPH10503656A (de)
AT (1) ATE291614T1 (de)
AU (1) AU700490B2 (de)
CA (1) CA2196776A1 (de)
DE (1) DE69534100T2 (de)
WO (1) WO1996004019A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140098A (en) * 1996-08-30 2000-10-31 Schering Corporation Nucleic acids encoding mammalian proteinases; related reagents
CA2268069A1 (en) * 1996-10-04 1998-04-09 Chronix Biomedical Diagnostic detection of nucleic acids
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
CN1441677A (zh) * 2000-03-31 2003-09-10 Idec药物公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
DE60219627T2 (de) 2001-06-04 2008-02-07 The General Hospital Corp., Boston Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
US20030064965A1 (en) * 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
US20030186246A1 (en) * 2002-03-28 2003-10-02 Willey James C. Multiplex standardized reverse transcriptase-polymerase chain reacton method for assessment of gene expression in small biological samples
NO326130B1 (no) * 2002-10-08 2008-10-06 Enok Tjotta Fremgangsmate for seleksjon og testing av forbindelser som inhiberer eller stimulerer klonal cellevekst
WO2006103659A2 (en) * 2005-03-30 2006-10-05 Yeda Research And Development Co. Ltd. Methods and systems for generating cell lineage tree of multiple cell samples
CA2623203C (en) * 2005-09-23 2014-08-12 Pathologica, Llc Methods for treating viral infections using polyamine analogs
US20070202515A1 (en) * 2005-10-12 2007-08-30 Pathologica, Llc. Promac signature application
EP2054058B1 (de) 2006-08-04 2016-11-09 Beth Israel Deaconess Medical Center Pyruvatkinasehemmer und verfahren zur behandlung von erkrankungen
EP2121586B1 (de) 2007-03-09 2017-03-08 Pathologica LLC Mgbg zur osteopontin-regelung und behandlung von multipler sklerose
EP2310508A1 (de) * 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Multitarget-bindungsproteine mit tnf-?-antagonist
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
NZ628513A (en) 2009-07-16 2016-01-29 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
EP2563761A1 (de) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Aktivatoren der menschlichen pyruvatkinase
ES2662373T3 (es) 2011-01-19 2018-04-06 Pathologica, Llc. Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
WO2012112245A1 (en) 2011-02-14 2012-08-23 Beth Israel Deaconess Medical Center, Inc. Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
EP3831372A1 (de) 2013-01-08 2021-06-09 Pathologica LLC Mitoguazon zur verhinderung des rückfalls oder des fortschreitens der multiplen sklerose
WO2017044720A1 (en) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
MX2018004674A (es) 2015-10-23 2018-09-11 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
EP3389664A4 (de) 2015-12-14 2020-01-08 Raze Therapeutics Inc. Koffeininhibitoren von mthfd2 und verwendungen dafür
EP3426243B1 (de) 2016-03-09 2021-05-19 Raze Therapeutics, Inc. 3-phosphoglycerat-dehydrogenase-inhibitoren und verwendungen davon
US11014882B2 (en) 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
AU2018258355B2 (en) 2017-04-26 2024-05-30 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
RU2020112854A (ru) 2017-11-30 2021-12-30 Арракис Терапьютикс, Инк. Фотозонды, связывающие нуклеиновые кислоты, и способы их применения
EP3759494A4 (de) * 2018-02-27 2022-01-26 The Board of Trustees of the Leland Stanford Junior University Manipulierte immunzellen als diagnostische sonden einer krankheit
DK3813946T3 (da) 2018-06-15 2024-08-19 Janssen Pharmaceutica Nv Rapamycin-analoger og anvendelser deraf
EP3870158A4 (de) 2018-10-24 2022-08-10 Navitor Pharmaceuticals, Inc. Polymorphe verbindungen und verwendungen davon
US11723890B2 (en) 2019-11-01 2023-08-15 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4681840A (en) * 1984-01-18 1987-07-21 The United States Of America As Represented By The Secretary Of Commerce Deoxyribonucleic acid molecules useful as probes for detecting oncogenes incorporated into chromosomal DNA
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5177192A (en) * 1987-04-02 1993-01-05 Centocor, Incorporated Method for labeling antibodies with a metal ion
US4869903A (en) * 1987-05-29 1989-09-26 Genelabs Incorporated Method of selectively inhibiting HIV
US4795739A (en) * 1987-05-29 1989-01-03 Gene Labs, Inc. Method of inhibiting HIV
US5180816A (en) * 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
EP0567575B1 (de) * 1991-01-14 1999-10-13 New York University Cytokin-induziertes protein, tsg-6, seine dna und verwendung
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease

Also Published As

Publication number Publication date
JPH10503656A (ja) 1998-04-07
ATE291614T1 (de) 2005-04-15
AU3403795A (en) 1996-03-04
CA2196776A1 (en) 1996-02-15
EP0772456B1 (de) 2005-03-23
EP0772456A1 (de) 1997-05-14
AU700490B2 (en) 1999-01-07
DE69534100T2 (de) 2006-03-23
EP0772456A4 (de) 1999-06-30
WO1996004019A1 (en) 1996-02-15
US5639600A (en) 1997-06-17

Similar Documents

Publication Publication Date Title
DE69534100D1 (de) Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen
CY1122817T1 (el) Νεα αντι-il 13 αντισωματα και χρησεις αυτων
ATE230614T1 (de) Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
ATE435281T1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
DE69231245D1 (de) Veraendertes gen bei menschlichem colorektalem-krebs
DE69933989D1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
DE69520499D1 (de) Histidine und homohistidine derivate zur verwendung als protein farnesyltransferase hemmstoffe
UY23910A1 (es) Procedimiento para la preparacion de 5- derivados sustitutivos del acido micofenolico
ATE324119T1 (de) Verwendung von saccharid-konjugaten
NO20002979L (no) Undersøkelse av human papillomavirus-relatert sykdom
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
UY25263A1 (es) 6-derivados sustitutivos del ácido micofenólico.-
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
CY1107780T1 (el) Μεθοδος για τη θεραπεια οφθαλμικων νεοαγγειακων ασθενειων
DE602004020266D1 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
DE69911380D1 (de) Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
BR0010702A (pt) Novas quinonas como terapias de doenças
DE69934694D1 (de) Bpc-1: ein ausgeschiedenes gehirnspezifisches protein das von prostata- und blasen-krebszellen exprimiert und ausgeschieden wird
EP1605847A4 (de) Gegen antikörper gerichtete photodynamische therapie
ATE311871T1 (de) Verwendung von zinksalzen der konjugierten linoleinsäuren zur behandlung von hautkrankheiten
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
TR200200278T2 (tr) Kalsilitik bileşimler

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee